TW EN

scroll

Go Top

Overview

TCTC

The goals of the Taiwan Lung Cancer Clinical Trial Consortium (TALCC) are advancing lung cancer treatments and improving the treatment outcome of lung cancer patients. In 2011, we gathered lung cancer clinical trial experts from major hospitals in Taiwan to form TALCC.

We aim to form collaborative effort to perform clinical trials that benefit lung cancer patients. Moreover, TALCC provides a platform for the pharmaceutical companies to promote new drugs and clinical trials from the laboratory to clinical applications.

One of the aims of TALCC is to improve clinical trial activities and accrual efficacy. In addition, TALCC members can share research activities and exchange experience in clinical trial.

We hope that Taiwan continues to be a global leading country in lung cancer clinical trials and new drug development. Furthermore, we will be able to provide patients with effective new treatments.

Strengths

TCTC

• The gene mutations of lung cancer patients in Asians are very different from Westerners. For instance, Asians have a much higher incidence rate of the epidermal growth factor receptor (EGFR) mutations than Westerners. Therefore, there are many related clinical trials that choose to conduct in Asia. We have launched many new targeted therapies since then.

• We also cooperate with many domestic biotechnology companies. We hope that the new lung cancer treatments that developed in Taiwan through the clinical trials can truly benefit patients.

• We accumulate the clinical trial data of the partner hospitals and aid whenever they have related questions.

Major Achievements

TCTC

International collaboration aspects

There are countless therapies launched after TALCC performed the clinical trials. Such as the ones listed below:
  • Tyrosine Kinase Inhibitors (TKI): EGFR: gefitinib(IRESSA®) MET exon 14 skipping mutation: tepotinib, capmatinib EGFR exon 20: mobocertinib, amivantamab ALK: ceritinib ( ZYKADIA®), alectinib (ALECENSA®), Brigatinib ( ALUNBRIG®), Lorlatinib (LORQUIVA®), KRAS:sotorasib ROS1: crizotinib(XALKORI®), entrectinib RET: selpercatinib
  • Chemotherapy: pemetrexed (Alimta®)
  • Immune therapy: pembrolizumab(KEYTRUDA®), Nivolumab( OPDIVO®), Atezolizumab(TECENTRIQ®), Durvalumab (IMFINZI®)
 

Social and other aspects

  • We gathered hospitals to recruit patients together, so that we can solve the slow-recruiting problems.
  • Because of TALCC, we have a platform that hospitals are able to communicate and execute better, moreover, with better data collection and storage. We also provide good resources for clinical trials initiated by investigators.
  • TALCC played major role for the launch of afatinib and osimertinib in the world.

Members

TCTC

NTUCM, NTU Cancer Center

NTU BioMedical Park Hospital

VGH-TPE

Tri-Service General Hospital

Dalin Tzu Chi Hospital

Contact Information

c-IRB

Ya-Hsin Wu

Email:122318@ntuh.gov.tw

TEL:(02)23123456 ext #66642